{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:36:50Z","timestamp":1793356610232,"version":"4.5.0"},"reference-count":125,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  Background: Gastroesophageal Reflux Disease (GERD) is a prevalent condition in Brazil, affecting 12% to 20% of the urban population, with significant implications for patient quality of life and potential for complications.  Objective: This paper focuses on the recent update of the Brazilian guidelines for GERD, a necessary revision due to advancements in knowledge and practice since the last publication over a decade ago. The update pays particular attention to the role and safety of proton pump inhibitors (PPIs), acknowledging the growing concerns about their long-term use, adverse events, and overprescription.  Methods: The methodology of the guideline update involved an extensive literature review in multiple languages (English, French, Italian, Spanish, and Portuguese), drawing from major databases such as Medline, Embase, and SciELO-Lilacs.  Results:  This comprehensive approach resulted in a carefully curated selection of studies, systematic reviews, and meta-analyses, specifically focusing on PPIs and other therapeutic strategies for GERD. The updated guidelines are presented in a user-friendly question-and-answer format, adhering to the PICO system (Population, Intervention, Comparison, Outcomes) for clarity and ease of interpretation. The recommendations are supported by robust scientific evidence and expert opinions, enhancing their practical applicability in clinical settings. To ensure the reliability and clarity of the recommendations, the GRADE system (Grading of Recommendations Assessment, Development, and Evaluation) was employed. This system categorizes the strength of recommendations as strong, weak, or conditional and classifies evidence quality as high, moderate, low, or very low. These classifications provide insight into the confidence level of each recommendation and the likelihood of future research impacting these guidelines.  Conclusion: The primary aim of these updated guidelines is to offer practical, evidence-based advice for the management of GERD in Brazil, ensuring that healthcare professionals are equipped with the latest knowledge and tools to deliver optimal patient care.<\/jats:p>","DOI":"10.1590\/s0004-2803.24612023-154","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T18:15:37Z","timestamp":1710526537000},"source":"Crossref","is-referenced-by-count":7,"title":["BRAZILIAN CLINICAL GUIDELINE FOR THE THERAPEUTIC MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE (BRAZILIAN FEDERATION OF GASTROENTEROLOGY, FBG)"],"prefix":"10.1590","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1280-6047","authenticated-orcid":false,"given":"Joaquim Prado P","family":"MORAES-FILHO","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0431-451X","authenticated-orcid":false,"given":"Gerson","family":"DOMINGUES","sequence":"additional","affiliation":[{"name":"Universidade do Estado do Rio de Janeiro,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-6687","authenticated-orcid":false,"given":"Decio","family":"CHINZON","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1590\/S0004-28032005000200011","article-title":"Prevalence of heartburn and gastroesophageal reflux disease in the urban Brazilian population","volume":"42","author":"Moraes-Filho JPP","year":"2005","journal-title":"Arq Gastroenterol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1590\/S0004-28032010000100017","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease: an evidence-based consensus","volume":"47","author":"Moraes-Filho JPP","year":"2010","journal-title":"Arq Gastroenterol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1111\/j.1572-0241.2006.00844.x","article-title":"Proton pump inhibitory therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controled trials","volume":"101","author":"Qader MA","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1365-2036.2010.04406.x","article-title":"Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies","volume":"32","author":"El-Serag H","year":"2010","journal-title":"Alim Pharmacol ther"},{"key":"ref5","first-page":"9865963","article-title":"A meta-analysis and systematic review of efficacy of twice daily PPIs versus once daily for treatment of gastroesophageal reflux disease","author":"Zhang H","year":"2017","journal-title":"Gastroenterol Res Pract"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41395-018-0045-4","article-title":"Management options for patients with GERD and persistent symptoms on proton pump inhibitors: Recommendations from an expert panel","volume":"113","author":"Yadlapati R","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","article-title":"ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease","volume":"117","author":"Katz PO","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"ref8","first-page":"3","article-title":"A estrat\u00e9gia PICO para constru\u00e7\u00e3o da pergunta de pesquisa e busca de evid\u00eancias","volume":"15","author":"Santos CMC","year":"2007","journal-title":"Rev Lat Am Enferm"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/apnr.2002.34181","article-title":"Popping the (PICO) question in research and evidence-based practice","volume":"15","author":"Stone PW","year":"2002","journal-title":"Appl Nurs Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines:1. Introduction-Grade evidence profiles and summary of finding tables","volume":"64","author":"Guyatt G","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE-guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem H","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/00365520510011579","article-title":"High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report","volume":"40","author":"Ronkainen J","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"ref13","article-title":"Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastroesophageal reflux disease-like symptoms and endoscopy negative reflux disease","volume":"3","author":"Sigterman KE","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000219365","article-title":"Diagnosis and Management of Non-Erosive Reflux Disease - The Vevey NERD Consensus Group","volume":"80","author":"Modlin IM","year":"2009","journal-title":"Digestion"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/apt.15062","article-title":"Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis","volume":"49","author":"Oshima T","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"8408","DOI":"10.3748\/wjg.v19.i45.8408","article-title":"Proton pump inhibitor for non-erosive reflux disease: A meta-analysis","volume":"19","author":"Zhang JX","year":"2013","journal-title":"World J Gastroenterol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/apt.13331","article-title":"Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis","volume":"42","author":"Ashida K","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2036.2006.02798.x","article-title":"Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn","volume":"23","author":"DeVault KR","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3892\/br.2017.947","article-title":"Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease","volume":"793","author":"Shinozaki S","year":"2017","journal-title":"Biomed Rep"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/archinte.166.9.965","article-title":"Are lifestyle measures effective in patients with gastroesophageal reflux disease ? An evidence-based approach","volume":"166","author":"Kaltenbach T","year":"2006","journal-title":"Arch Intern Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1056\/NEJMoa054391","article-title":"Body-mass index and symptoms of gastroesophageal reflux in women","volume":"354","author":"Jacobson BC","year":"2006","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMcp2114026","article-title":"Gastroesophageal Reflux Disease","volume":"387","author":"Fass R","year":"2022","journal-title":"N Engl J Med"},{"key":"ref23","article-title":"AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease. Expert Review.","volume":"21","author":"Chen JW","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref24","first-page":"1","article-title":"Use a positional therapy device significantly improves nocturnal gastroesophageal symptoms","volume":"30","author":"Allampati S","year":"2017","journal-title":"Dis Esophagus"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1440-1746.2011.06968.x","article-title":"Effect of bed head elevation during sleep in symptomatic patients of nocturnal gastroesophageal reflux","volume":"27","author":"Khan BA","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/00365520310004506","article-title":"Cigarette smoking and alcohol comsumption associated with gastro-esophageal reflux disease in Japanese men","volume":"38","author":"Watanabe Y Fujiwara","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ajg.2013.414","article-title":"Tobacco smoking cessation and improved gastroesophageal reflux: a prospective population based cohort study. The HUNT study.","volume":"109","author":"Ness-Jensen E","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0016-5085(78)90410-9","article-title":"Food sensitivity in reflux esophagitis","volume":"75","author":"Price SF","year":"1978","journal-title":"Gastroenterology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/MCG.0000000000000359","article-title":"A novel sleep positioning devices reduces gastroesophageal reflux: a randomized controlled trial","volume":"49","author":"Person E","year":"2015","journal-title":"J Clin Gastroenterol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1001\/jama.2020.21360","article-title":"Gastroesophageal reflux disease. A review","volume":"324","author":"Maret-Ouda J","year":"2020","journal-title":"JAMA"},{"key":"ref31","article-title":"American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease","volume":"135","author":"Kahrilas PJ","year":"2008","journal-title":"Gastroenterology"},{"key":"ref32","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2015.04.176","article-title":"Life style intervention in gastroesophageal reflux disease","volume":"14","author":"Ness-Jensen E","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/gut.2004.040337","article-title":"Dietary intake and the risk if gastroesophageal reflux disease. A cross sectional study in volunteers","volume":"54","author":"El-Serag HB","year":"2005","journal-title":"Gut"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamainternmed.2020.7238","article-title":"Association of diet and lifestyle with the risk of gastroesophageal reflux disease symptoms in US women","volume":"181","author":"Mehta RS","year":"2021","journal-title":"JAMA Intern Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5056\/jnm19053","article-title":"Efficacy of S-pantoprazole 10 mg in the Symptom Control of Non-erosive Reflux Disease: A Phase III Placebo-controlled Trial","volume":"27","author":"Cho YK","year":"2021","journal-title":"J Neurogastroenterol Motil"},{"issue":"18","key":"ref36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12876-018-0790-2","article-title":"Sustained efficacy following resolution of frequent heartburn with an over-the-counter regimen of esomeprazole 20 mg or placebo for 14 days: two randomized trials","volume":"22","author":"Peura DA","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.clinthera.2017.03.015","article-title":"Analysis of 2-Week Data from Two Randomized, Controlled Trials Conducted in Subjects with Frequent Heartburn Treated with Esomeprazole 20 mg","volume":"39","author":"Katz PO","year":"2017","journal-title":"Clin Ther"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s00535-011-0402-1","article-title":"Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial","volume":"46","author":"Tan VP","year":"2011","journal-title":"J Gastroenterol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3748\/wjg.15.990","article-title":"Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis","volume":"15","author":"Zheng RN","year":"2009","journal-title":"World J Gastroenterol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.cgh.2006.09.013","article-title":"Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials","volume":"4","author":"Gralnek IM","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref41","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2017.09.033","article-title":"Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency","volume":"16","author":"Graham DY","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/j.1365-2036.2010.04272.x","article-title":"The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor","volume":"31","author":"Lee RD","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"ref43","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000101","article-title":"Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study","volume":"10","author":"Kinoshita Y","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/gutjnl-2019-318365","article-title":"Phase III, randomized, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis","volume":"69","author":"Xiao Y","year":"2020","journal-title":"Gut"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10620-018-5365-0","article-title":"Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan","volume":"64","author":"Sakurai K","year":"2019","journal-title":"Dig Dis Sci"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2016.12.001","article-title":"Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study","volume":"81-82:","author":"Kinoshita Y","year":"2016","journal-title":"Curr Ther Res Clin Exp"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","article-title":"Randomized clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis","volume":"43","author":"Ashida K","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1572-0241.2007.01544.x","article-title":"A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease","volume":"103","author":"Dent J","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10620-020-06141-5","article-title":"Vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: a systematic review and meta-analysis","volume":"66","author":"Cheng Y","year":"2021","journal-title":"Dig Dis Sci"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1053\/j.gastro.2022.09.041","article-title":"Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial","volume":"164","author":"Laine L","year":"2023","journal-title":"Gastroenterology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.3748\/wjg.v20.i9.2412","article-title":"Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis","volume":"20","author":"Ren LH","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.15171\/mejdd.2018.124","article-title":"Evaluation of the additive effect of domperidone on patients with refractory gastroesophageal reflux disease; a randomized double blind clinical trial","volume":"11","author":"Tghvaei T","year":"2019","journal-title":"Middle East J Dig Dis"},{"key":"ref53","first-page":"1","article-title":"Gastrointestinal pharmacology: practical tips for the esophagologist","author":"Scarpignato C","year":"2020","journal-title":"Ann N Y Acad Sci"},{"key":"ref54","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14075","article-title":"ESNM\/ANMS consensus paper: diagnosis and management of refractory gastroesophageal reflux disease","volume":"33","author":"Zerbib F","year":"2021","journal-title":"Neurogastroenterol Motil"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cgh.2020.03.056","article-title":"Management of chronic abdominal distension and bloating","volume":"19","author":"Lacy BE","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/apt.17068","article-title":"Clinical trial: a controlled trial of baclofen add-on therapy in PPI refractory gastro-oesophageal reflux symptoms","volume":"56","author":"Pauwels A","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"ref57","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14181","article-title":"Low FODMAPs diet or usual dietary advice for the treatment of refractory gastroesophageal reflux disease: An open-labeled randomized trial","volume":"33","author":"Rivi\u00e8re P","year":"2021","journal-title":"Neurogastroenterol Motil"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1811424","article-title":"Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn","volume":"381","author":"Spechler SJ","year":"2019","journal-title":"N Engl J Med"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/1756283X17705329","article-title":"A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis","volume":"10","author":"Iwakiri K","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2016.11.002","article-title":"A Multicenter, Randomized, Open-Label Trial: Efficacy of Once-Daily Versus Twice-Daily Double-Dose Rabeprazole on Refractory Gastroesophageal Reflux Disease-Related Symptoms and Quality of Life","volume":"79","author":"Mizuki A","year":"2016","journal-title":"Curr Ther Res Clin Exp"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1046\/j.1365-2036.2000.00882.x","article-title":"Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study","volume":"14","author":"Fass R","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2147\/DDDT.S306371","article-title":"Pharmacological management of gastro-esophageal reflux disease: an update of the state-of-the-art","volume":"15","author":"Savarino V","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/apt.14986","article-title":"Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease","volume":"48","author":"Ribolsi M","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2036.2003.01394.x","article-title":"Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH","volume":"17","author":"Vela MF","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"ref65","article-title":"On-demand versus half-dose continuos therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease. A randomized comparative study","volume":"43","author":"Cho JH","year":"2018","journal-title":"Medicine"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3748\/wjg.v24.i14.1550","article-title":"Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole","volume":"24","author":"Ashida K","year":"2018","journal-title":"World J Gastroenterol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12876-016-0448-x","article-title":"Randomized multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease","volume":"16","author":"Bayerd\u00f6rffer E","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/00365521.2013.878380","article-title":"A randomized prospective study comparing the efficacy of on-demand therapy versus continuous therapy for 6 months for long term maintenance with omeprazole 20mg in patients with gastroesophageal reflux disease in Japan","volume":"49","author":"Nagahara A","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1365-2036.2010.04254.x","article-title":"Clinical trial: maintenance intermitent therapy with rabeprazole 20mg in patients with symptomatic gastroesophageal reflux disease : a double-blind, placebo-controlled, randomized study","volume":"31","author":"Fass R","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"ref70","first-page":"67","article-title":"Maintenance therapy of gastroesophageal reflux disease patients with omeprazole","volume":"56","author":"Tepes B","year":"2009","journal-title":"Hepatogastroenterology"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1155\/2007\/203201","article-title":"Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg","volume":"21","author":"Morgan DG","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"ref72","first-page":"205","article-title":"Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance oh healed gastroesophageal reflux disease: a randomized double-blind comparative trial - the EMANCIPATE study","volume":"19","author":"Gohl KL","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2036.2005.02553.x","article-title":"Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive esophagitis","volume":"22","author":"Sj\u00f6stedt S","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1365-2036.2005.02413.x","article-title":"Long term treatment of gastroesophageal reflux disease patients with frequent symptomatic relapsesusing rabeprazole on-demand treatment compared with continuous treatment","volume":"21","author":"Bour B","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000087661","article-title":"On demand therapy with pantoprazole 20 mg as effective long term management of reflux diseases in patinets with mild GERD: the ORION trial","volume":"72","author":"Scholten T","year":"2005","journal-title":"Digestion"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2036.2004.02155.x","article-title":"Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lanzoprazole 15 mg in the long-term maintenance of endoscopy-negative gastroesophageal reflux patients: the COMMAND study","volume":"20","author":"Tsai HH","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/00042737-200208000-00008","article-title":"Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months","volume":"14","author":"Talley NJ","year":"2002","journal-title":"Eur J Gastroenterol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2036.2001.00943.x","article-title":"Esomeprazole 20 mg maintain symptoms in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of \u201con-demand\u201d therapy for 6 months","volume":"15","author":"Talley NJ","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/gut.33.8.1016","article-title":"Three year follow-up of patients with gastroesophageal reflux disease","volume":"33","author":"Schindlbeck NE","year":"1992","journal-title":"Gut"},{"key":"ref80","article-title":"Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxabanor aspirin","volume":"1579","author":"Moyayyedi P","year":"2019","journal-title":"Gastroenterology"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterology Association","volume":"152","author":"Freedberg DE","year":"2017","journal-title":"Gastroenterology"},{"key":"ref82","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017788","article-title":"Proton pump inhibitors and hypomagnesemia: a meta-analysis of observational studies","volume":"98","author":"Srinutta T","year":"2019","journal-title":"Medicine"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","article-title":"Proton pump inhibitor use and the risk of chronic kidney disease","volume":"176","author":"Lazarus B","year":"2016","journal-title":"JAMA Intern Med"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1053\/j.gastro.2017.05.046","article-title":"Association between proton pump inhibitor use and risk of progression of chronic kidney disease","volume":"153","author":"Klatte DCF","year":"2017","journal-title":"Gastroenterology"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"2042098618809927","DOI":"10.1177\/2042098618809927","article-title":"The risks of long term use of proton pump inhibitors: a critical review","volume":"10","author":"Jaynes M","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/apt.13568","article-title":"A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors","volume":"43","author":"Clooney AG","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-149-6-200809160-00005","article-title":"Proton pump inhibitor use and the risk for community adquired pneumonia","volume":"149","author":"Sarkar M","year":"2008","journal-title":"Ann Intern Med"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/apt.13450","article-title":"Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors","volume":"43","author":"Schneider JL","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"ref89","first-page":"541","article-title":"Side effects of long-term use of proton pump inhibitors: practical considerations","volume":"131","author":"Castellana C","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11894-020-00780-4","article-title":"Non-acid Reflux: When It Matters and Approach to Management","volume":"22","author":"Zicos TA","year":"2020","journal-title":"Curr Gastroenterol Rep"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/j.1365-2036.2005.02677.x","article-title":"Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian-French cohort of healthy subjects","volume":"22","author":"Zerbib F","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/j.1572-0241.2004.04172.x","article-title":"Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers","volume":"99","author":"Shay S","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2036.2007.03527.x","article-title":"Review article: the measurement of non-acid gastroesophageal reflux","volume":"26","author":"Zerbib F","year":"2007","journal-title":"Aliment Pharmacol ther"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1136\/gut.2003.033290","article-title":"Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux","volume":"53","author":"Sifrim D","year":"2004","journal-title":"Gut"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s10620-017-4625-8","article-title":"Impedance-pH monitoring for diagnosis of disease:new perspectives","volume":"62","author":"Frazzoni M","year":"2017","journal-title":"Dig Dis Sci"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/jgh.13049","article-title":"Tailored therapy for the refractory GERD patients by combined multichannel intraluminal impedance-pH monitoring","volume":"31","author":"Xiao Y","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1136\/gut.2009.194191","article-title":"Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus","volume":"59","author":"Farr\u00e9 R","year":"2010","journal-title":"Gut"},{"key":"ref98","first-page":"307","article-title":"The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials","volume":"2014","author":"Li S","year":"2014","journal-title":"Gastroenterol Res Pract"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1007\/s00464-021-08358-5","article-title":"Surgical treatment of GERD: systematic review and meta-analysis","volume":"35","author":"McKinley SK","year":"2021","journal-title":"Surg Endosc"},{"key":"ref100","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.chest.2016.08.1458","article-title":"Chronic cough due to gastroesophageal reflux in adults: CHEST guideline and expert panel report","volume":"150","author":"Kahrilas PJ","year":"2016","journal-title":"Chest"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s00464-011-1585-5","article-title":"Randomized controlled trial of laparoscopic Nissen fundoplication versus proton pump inhibitors for the treatment of patients with chronic gastroesophageal reflux disease (GERD): 3-years outcomes","volume":"25","author":"Anvari M","year":"2011","journal-title":"Surg Endosc"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.2011.626","article-title":"Laparoscopic antireflux surgery versus esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial","volume":"305","author":"Galmiche JP","year":"2011","journal-title":"JAMA"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/00042737-200012080-00007","article-title":"Long term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial","volume":"12","author":"Lundell L","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref104","first-page":"198","article-title":"Seven-year follow-up of a randomized clinical trial comparing proton pump inhibition with surgical therapy for reflux oesophagitis","volume":"94","author":"Lundell L","year":"2007","journal-title":"Surg"},{"key":"ref105","first-page":"1","article-title":"Diagnostic and therapeutic management in gastroesophageal reflux disease: consensus of the Polish Society of Gastroenterology","volume":"132","author":"Swidnicka-Siergiejko AK","year":"2022","journal-title":"Polskie Archiwum Medycyny Wewnetrznej"},{"key":"ref106","article-title":"Magnetic sphincter augmentation superior to proton pump inhibitors for regurgitation in a 1-year randomized trial","volume":"135","author":"Bell R","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref107","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.10.009","article-title":"Efficacy of transoral fundoplication vs omeprazole for treatment of regurgitation in a randomized controlled trial","volume":"148","author":"Hunter JG","year":"2015","journal-title":"Gastroenterology"},{"key":"ref108","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2022.01.025","article-title":"AGA Clinical Practice Update on the Personalized Approach to the evaluation and Management of GERD: Expert Review","volume":"20","author":"Yadlapati R","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.giec.2019.12.008","article-title":"Transoral Incisionless Fundoplication","volume":"30","author":"Chang KJ","year":"2020","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s00464-016-5111-7","article-title":"Efficacy of transoral incionless fundoplication (TIF) for the treatment of GERD: a systematic review with meta-analysis","volume":"31","author":"Huang X","year":"2017","journal-title":"Surg Endosc"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"6601","DOI":"10.3748\/wjg.v27.i39.6601","article-title":"Endoscopic anti-reflux therapy for gastroesophageal reflux disease","volume":"27","author":"Santiago ER","year":"2021","journal-title":"World Gastroenterol"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1007\/s00464-017-5431-2","article-title":"Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease","volume":"31","author":"Fass R","year":"2017","journal-title":"Surg Endosc"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0016-5085(03)01052-7","article-title":"Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham- controlled trial","volume":"125","author":"Corley DA Katz P","year":"2003","journal-title":"Gastroenterology"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1053\/gast.2001.27997","article-title":"Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal","volume":"121","author":"Fletcher J","year":"2001","journal-title":"Gastroenterology"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"642","DOI":"10.5009\/gnl18378","article-title":"The Clinical Efficacy of a Pure Alginate Formulation (Lamina G) for Controlling Symptoms in Individuals with Reflux Symptoms: A Randomized Clinical Study","volume":"13","author":"Kim JH","year":"2019","journal-title":"Gut Liver"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/apt.13567","article-title":"Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor","volume":"43","author":"Reimer C","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/apt.13334","article-title":"Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China","volume":"42","author":"Sun J","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/apt.12640","article-title":"Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease","volume":"39","author":"Thomas E","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/apt.12482","article-title":"Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease","volume":"38","author":"Chiu CT","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"ref120","first-page":"12","article-title":"Gaviscon\u00ae vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. A direct comparative randomised trial","volume":"23","author":"Pouchain D","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1185\/03007999909114086","article-title":"A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease","volume":"15","author":"Chatfield S","year":"1999","journal-title":"Curr Med Res Opin"},{"key":"ref122","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/gutjnl-2017-314722","article-title":"Modern diagnosis of GERD: the Lyon Consensus","volume":"67","author":"Gyawali CP","year":"2018","journal-title":"Gut"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.cgh.2012.06.030","article-title":"Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease","volume":"10","author":"Bytzer P","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.gastro.2017.07.049","article-title":"Management of Gastroesophageal Reflux Disease","volume":"154","author":"Gyawali CP","year":"2018","journal-title":"Gastroenterology"},{"key":"ref125","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1111\/nmo.12666","article-title":"Majority of symptoms in esophageal reflux PPI non-responders are not related to reflux","volume":"27","author":"Roman S","year":"2015","journal-title":"Neurogastroenterol Motil"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":["Diretriz brasileira de conduta terap\u00eautica na doen\u00e7a do refluxo gastroesof\u00e1gico (Federa\u00e7\u00e3o Brasileira de Gastroenterologia, FBG)"],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0004-28032024000100208&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T18:16:34Z","timestamp":1710526594000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032024000100208&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":125,"alternative-id":["S0004-28032024000100208"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.24612023-154","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e23154"}}